No Data
No Data
Do Its Financials Have Any Role To Play In Driving Northeast Pharmaceutical Group Co., Ltd.'s (SZSE:000597) Stock Up Recently?
Tohoku Pharmaceutical: 2024 Semi-Annual Report Summary
Tohoku Pharmaceutical: Semi-Annual Report 2024
Northeast Pharmaceutical Group (000597.SZ): The net income in the first half of the year was 0.157 billion yuan, an increase of 16.25% year-on-year.
On August 27th, Northeast Pharmaceutical Group (000597.SZ) released its semi-annual report, with revenue of 4.169 billion yuan, a decrease of 7.50% year-on-year, net income of 0.157 billion yuan, an increase of 16.25% year-on-year, non-GAAP net income of 0.1 billion yuan, an increase of 27.58% year-on-year, and basic earnings per share of 0.110 yuan.
Northeast Pharmaceutical Group (000597.SZ): The product pipeline of Dingcheng Peptide Source is in the preclinical research and clinical declaration stage. The company has no substantial income at this stage.
On August 8th, Gelunhui reported that Northeast Pharmaceutical Group (000597.SZ) announced a stock price anomaly notice and signed an Equity Acquisition Framework Agreement with Mr. Zhang Rong. The company intends to acquire 70% of the equity of Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. (referred to as 'Dingcheng Peptide Source') with this agreement, which is only a framework agreement for equity acquisition. The specific matters concerning equity acquisition still need to be finalized based on evaluation results, and the transaction arrangement is subject to the formal equity transfer agreement signed by all parties to the transaction. There are still uncertainties in this equity acquisition. As of now, Dingcheng Peptide Source's product pipeline is in the pre-clinical research and clinical declaration stages during this stage.
Northeast Pharmaceutical Group (000597.SZ): Currently, the outlook for vitamin C products is not as pessimistic as before.
On August 8th, Gelonhui reported that Northeast Pharmaceutical Group (000597.SZ) stated during an investor relations event that they are not as pessimistic about vitamin C products as before. They have shifted their focus from supply-demand relations to the quality and excellence of their products.
No Data
No Data